Investor Presentation via Investor Meet Company

Summary by AI ^BETAClose X

BioPharma Credit PLC has announced that its Investment Adviser, Pharmakon Advisors, LP, will host a live investor presentation on April 21, 2026, at 15:00 BST via Investor Meet Company. This session is open to both existing and potential shareholders and will focus on the company's investment strategy and portfolio. Questions can be submitted in advance by April 20, 2026, at 09:00 BST, or during the presentation itself.

Disclaimer*

BioPharma Credit PLC

10 April 2026

BioPharma Credit PLC

(the "Company")

Investor Presentation via Investor Meet Company

BioPharma Credit PLC announces that the Company's Investment Adviser, Pharmakon Advisors, LP, will provide a live presentation via Investor Meet Company on 21 April 2026 at 15:00 BST.

The presentation is open to existing and potential shareholders and will provide an overview of the Company's investment strategy and portfolio.

Questions can be submitted pre-event via your Investor Meet Company dashboard up until 20 April 2026 at 09:00am BST, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet the Company via:

https://www.investormeetcompany.com/biopharma-credit-plc/register-investor

Investors who already follow the Company on the Investor Meet Company platform will automatically be invited.

- ENDS -

For further information:

Enquiries:

BioPharma Credit plc

via MUFG Corporate Governance Limited

Company Secretary

+44 (0) 333 300 1932

Burson Buchanan

Henry Wilson / Helen Tarbet / Jamie Hooper / Nick Croysdill

+44 (0)20 7466 5000

biopharmacredit@buchanan.uk.com

Notes to Editors:

BioPharma Credit PLC is London's only specialist debt investor to the life sciences industry and joined the LSE in March 2017. BioPharma Credit PLC seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. BioPharma Credit PLC seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END